Grifols Financial Statements From 2010 to 2024
| OZTA Stock | EUR 9.62 0.32 3.44% |
Check Grifols SA financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Grifols SA's main balance sheet or income statement drivers, such as , as well as many indicators such as . Grifols financial statements analysis is a perfect complement when working with Grifols SA Valuation or Volatility modules.
Grifols |
Grifols SA Company Return On Equity Analysis
Grifols SA's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Grifols SA Return On Equity | 0.0182 |
Most of Grifols SA's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Grifols SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Grifols SA has a Return On Equity of 0.0182. This is 100.08% lower than that of the Healthcare sector and 99.15% lower than that of the Drug Manufacturers - Major industry. The return on equity for all Germany stocks is 105.87% lower than that of the firm.
Grifols SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Grifols SA's current stock value. Our valuation model uses many indicators to compare Grifols SA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Grifols SA competition to find correlations between indicators driving Grifols SA's intrinsic value. More Info.Grifols SA is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.85 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Grifols SA is roughly 1.17 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Grifols SA's earnings, one of the primary drivers of an investment's value.About Grifols SA Financial Statements
Grifols SA stakeholders use historical fundamental indicators, such as Grifols SA's revenue or net income, to determine how well the company is positioned to perform in the future. Although Grifols SA investors may analyze each financial statement separately, they are all interrelated. For example, changes in Grifols SA's assets and liabilities are reflected in the revenues and expenses on Grifols SA's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Grifols SA. Please read more on our technical analysis and fundamental analysis pages.
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company was founded in 1940 and is headquartered in Barcelona, Spain. GRIFOLS SA operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 22282 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Grifols Stock
Grifols SA financial ratios help investors to determine whether Grifols Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Grifols with respect to the benefits of owning Grifols SA security.